Key result
Large extracellular vesicles from mesenchymal stem cells mitigated doxorubicin injury in patient-specific cardiomyocytes via mitochondrial transfer, improving viability and contractility.
Why the study?
Mesenchymal stem cells were evaluated for anthracycline-induced cardiomyopathy in the SENECA trial, but the mechanisms underpinning their efficacy in human tissue needed clarification.
Do MSC-derived large extracellular vesicles mitigate doxorubicin injury in patient-specific induced pluripotent stem cell-derived cardiomyocytes?
Population
Patient-specific iCMs generated from SENECA trial patients injured with 1 μmol/L DOX
Comparison
MSC-derived L-EVs vs small EVs or coculture vs direct incubation
Design
In vitro clinical trial
Authors
Loading...
MSC mechanisms clarified in human AIC tissue; extends SENECA but leaves open clinical translation.
Do MSC-derived large extracellular vesicles mitigate doxorubicin injury in patient-specific induced pluripotent stem cell-derived cardiomyocytes?
Large extracellular vesicles from mesenchymal stem cells mitigate doxorubicin-induced cardiomyocyte injury via mitochondrial transfer, providing a potential mechanism for MSC efficacy in anthracycline-induced cardiomyopathy.
O’Brien et al. (2021) studied Anthracycline-induced cardiomyopathy. Large extracellular vesicles (L-EVs) from mesenchymal stem cells vs. Small EVs or untreated was evaluated on Cardiomyocyte viability and markers of improved cellular physiology. Large extracellular vesicles from mesenchymal stem cells mitigated doxorubicin injury in patient-specific cardiomyocytes via mitochondrial transfer, improving viability and contractility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: